Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2022-02-09 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于盐酸恩沙替尼胶囊术后辅助治疗适应症药品临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Betta Pharmaceuticals Co., Ltd. regarding the acceptance of a clinical trial application for a new drug indication by the National Medical Products Administration (NMPA) in China. It details the acceptance notice, the drug involved, the clinical trial purpose, and the regulatory process. The document is an announcement of a regulatory event related to drug approval and clinical trial acceptance, not a financial report, earnings release, or management discussion. It is relatively short (1684 characters) and serves as a formal disclosure of regulatory progress. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-02-09 Chinese
2021年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2021 annual performance forecast (业绩预告) from 贝达药业股份有限公司, covering the full fiscal year from January 1, 2021 to December 31, 2021. It provides estimated net profit figures and explanations for performance changes but explicitly states that the forecast has not been audited and that detailed financial data will be disclosed in the 2021 annual report. The document is short (1219 characters) and serves as a preliminary earnings forecast rather than a full financial report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only, not the full annual report (10-K). FY 2021
2022-01-25 Chinese
关于BPI-442096片获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about receiving clinical trial approval from the National Medical Products Administration (NMPA) for a new drug candidate (BPI-442096). It details the approval notice, the drug's research background, and the impact on the company. The document is short (1412 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report types. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-01-24 Chinese
关于投资浙江时迈药业有限公司暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding an investment by the company (贝达药业) into another company (浙江时迈药业有限公司), which is described as a related party transaction. It includes information about the investment amount, the related parties involved, the approval process by the board and supervisory committee, and the impact and risks of the transaction. The document is structured as a formal announcement to shareholders and the public about a specific capital investment and related party transaction. It does not contain financial statements or comprehensive financial performance data typical of annual or interim reports. It also does not fit categories like earnings release, audit report, or management reports. The content aligns with a capital or financing update, specifically about an investment transaction and related party dealings. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (6641 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2022-01-23 Chinese
关于公司聘任高级管理人员的公告
Board/Management Information Classification · 100% confidence The document is an announcement from 贝达药业股份有限公司 regarding the appointment of a senior management personnel, specifically the hiring of Mr. 蔡万裕 as a senior vice president. It includes details about the board meeting approving the appointment, the individual's qualifications, and compliance with regulatory requirements. There is no financial data, earnings information, or report publication mentioned. The content clearly relates to management changes rather than financial results or other report types. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and focused solely on the appointment, confirming it is not a full report or announcement of a report publication.
2022-01-23 Chinese
第三届董事会第二十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of 贝达药业股份有限公司 (Betta Pharmaceuticals Co., Ltd.). It details the convening of the meeting, attendance, and the approval of several proposals including investment decisions and appointment of senior management. The document includes voting results and references to related announcements but does not contain financial statements or detailed financial data. It is primarily about board decisions and management appointments. Therefore, it fits the category of Board/Management Information (MANG). The document length is short (1847 characters), and it is not a report or a notice of report publication, so it is not an Annual Report or Report Publication Announcement.
2022-01-23 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.